A Phase 2b, Multicenter, Double-blind, Placebo-controlled Randomized Withdrawal Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat, ACPA-Positive Rheumatoid Arthritis
Latest Information Update: 10 Feb 2025
Price :
$35 *
At a glance
- Drugs IMVT-1402 (Primary)
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Sponsors Immunovant
- 05 Feb 2025 Status changed from not yet recruiting to recruiting.
- 07 Jan 2025 New trial record